Cargando…

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids

Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver disease (NAFLD). The non-absorbable antibiotic rifaximin has been used for treatment of irritable bowel syndrome, traveling diarrhea, and hepatic encephalopathy, but the efficacy of rifaximin in NASH patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jian, Jie, Nie, Mei-Tong, Xiang, Baoyu, Qian, Hui, Yin, Chuan, Zhang, Xin, Zhang, Menghui, Zhu, Xuan, Xie, Wei-Fen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017645/ https://www.ncbi.nlm.nih.gov/pubmed/35450049 http://dx.doi.org/10.3389/fphar.2022.841132

Ejemplares similares

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism
por: Lu, Yifei, et al.
Publicado: (2022)

Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo
por: Li, Hongshan, et al.
Publicado: (2023)

Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice
por: Li, Chunlin, et al.
Publicado: (2022)

Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet
por: Peng, Jing-hua, et al.
Publicado: (2018)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation
por: Shu, Xiangbing, et al.
Publicado: (2021)

Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism
por: Lei, Yuanyuan, et al.
Publicado: (2022)

Ameliorative effect of Aconite aqueous extract on diarrhea is associated with modulation of the gut microbiota and bile acid metabolism
por: Zhang, Dandan, et al.
Publicado: (2023)

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice
por: Li, Shengjie, et al.
Publicado: (2022)

Bear bile powder ameliorates type 2 diabetes via modulation of metabolic profiles, gut microbiota, and metabolites
por: Chen, Xing-Ling, et al.
Publicado: (2023)

Astragalus Polysaccharides Ameliorate Diet-Induced Gallstone Formation by Modulating Synthesis of Bile Acids and the Gut Microbiota
por: Zhuang, Qian, et al.
Publicado: (2021)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis
por: Yang, Zhen, et al.
Publicado: (2023)

Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites
por: Luo, Mei, et al.
Publicado: (2023)

Inulin ameliorates metabolic syndrome in high-fat diet-fed mice by regulating gut microbiota and bile acid excretion
por: Huang, Shaoxiong, et al.
Publicado: (2023)

Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy
por: Han, Xianghui, et al.
Publicado: (2021)

Gut-Derived Serotonin Contributes to the Progression of Non-Alcoholic Steatohepatitis via the Liver HTR2A/PPARγ2 Pathway
por: Wang, Lulu, et al.
Publicado: (2020)

Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2018)

Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice
por: Kasai, Kaichi, et al.
Publicado: (2023)

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2018)

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
por: Peng, Cheng, et al.
Publicado: (2020)

Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
por: Gillard, Justine, et al.
Publicado: (2021)

Lactiplantibacillus plantarum LPJZ-658 Improves Non-Alcoholic Steatohepatitis by Modulating Bile Acid Metabolism and Gut Microbiota in Mice
por: Liu, Liming, et al.
Publicado: (2023)

Diosgenin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Related Lipid/Amino Acid Metabolism in High Fat Diet-Fed Rats
por: Zhou, Yuan, et al.
Publicado: (2022)

Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design
por: Wang, Xinxue, et al.
Publicado: (2023)

Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice
por: Yamada, Shoji, et al.
Publicado: (2018)

The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against‐Non-Alcoholic Steatohepatitis
por: Hong, Wei, et al.
Publicado: (2020)

Extracts of Vine Tea Improve Diet-Induced Non-Alcoholic Steatohepatitis Through AMPK-LXRα Signaling
por: Chen, Yu-jun, et al.
Publicado: (2021)

Ferulic Acid Ameliorates Atherosclerotic Injury by Modulating Gut Microbiota and Lipid Metabolism
por: Gu, Yuyan, et al.
Publicado: (2021)

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
por: Yu, Lili, et al.
Publicado: (2022)

Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis
por: Luo, Wei, et al.
Publicado: (2023)

Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut–Liver Axis
por: Yang, Chao, et al.
Publicado: (2021)

Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice
por: Hartmann, Phillipp, et al.
Publicado: (2022)

Modulatory Effects of Huoxiang Zhengqi Oral Liquid on Gut Microbiome Homeostasis Based on Healthy Adults and Antibiotic-Induced Gut Microbial Dysbiosis Mice Model
por: Gao, Min, et al.
Publicado: (2022)

Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus
por: Gao, Ruolin, et al.
Publicado: (2022)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Naturally Occurring TPE-CA Maintains Gut Microbiota and Bile Acids Homeostasis via FXR Signaling Modulation of the Liver–Gut Axis
por: Liu, Linlin, et al.
Publicado: (2020)

Micronized Palmitoylethanolamide Ameliorates Methionine- and Choline-Deficient Diet–Induced Nonalcoholic Steatohepatitis via Inhibiting Inflammation and Restoring Autophagy
por: Hu, Jiaji, et al.
Publicado: (2021)

Gut Microbiota-Mediated Elevated Production of Secondary Bile Acids in Chronic Unpredictable Mild Stress
por: Qu, Yuchen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87svjq6hci2qhijh0bp5p8k6sc